皮下注射艾加莫德在慢性炎性脱髓鞘性多发性神经根神经病患者中的安全性、耐受性和疗效(ADHERE):一项多中心、随机撤药、双盲、安慰剂对照的2期试验
ADHERE试验纳入322例CIDP患者,开放标签阶段每周皮下注射1000mg艾加莫德PH20,214例(66%)确认临床改善后随机撤药,艾加莫德组较安慰剂显著降低复发风险(HR 0.39,95%CI 0.25-0.61,p<0.0001),安全性总体可接受,但需进一步研究长期疗效及与现有治疗的比较。
要点
- 对治疗有应答的CIDP患者中,皮下艾加莫德PH20较安慰剂显著降低复发风险(HR 0.39)。
- 开放标签阶段214/322例(66%,95%CI 61.0-71.6)达到确认的临床改善。
- 治疗中出现的不良事件:A阶段204例(63%),B阶段艾加莫德组71例(64%)vs 安慰剂组62例(56%)。
核心结论
- ADHERE试验显示,对治疗有应答的CIDP患者中,皮下艾加莫德PH20较安慰剂降低复发风险;需进一步研究长期疗效及与现有治疗的比较。
研究设计与样本
- ADHERE为多阶段、双盲、安慰剂对照试验,从亚太、欧洲和北美146个临床中心纳入CIDP患者。
- 有临床意义恶化证据者进入A阶段:每周皮下注射1000mg艾加莫德PH20,最长12周。
- 确认临床改善的治疗应答者进入B阶段:按1:1随机接受每周1000mg皮下艾加莫德PH20或安慰剂,最长48周。
- 随机分层因素为A阶段调整后INCAT评分变化和筛查前6个月内最近使用的CIDP药物。
主要发现
- 2020年4月15日至2023年5月11日筛查629例,322例(女114例,男208例)进入A阶段,214例(66%,95%CI 61.0-71.6)达到确认的临床改善。
- B阶段随机221例(女79例,男142例;艾加莫德组111例,安慰剂组110例)。
- 艾加莫德组31例(27.9%[95%CI 19.6-36.3])复发,安慰剂组59例(53.6%[95%CI 44.3-63.0])复发,风险比0.39(95%CI 0.25-0.61;p<0.0001)。
- A阶段治疗中出现的不良事件204例(63%),严重治疗中出现的不良事件21例(7%)。
- B阶段治疗中出现的不良事件:艾加莫德组71例(64%)vs 安慰剂组62例(56%);严重治疗中出现的不良事件两组各6例(5%)。
关键数值与推荐
- A阶段主要终点为确认的临床改善:aINCAT评分降低≥1分、INCAT Rasch-built Overall Disability Scale增加≥4分(centile metric)或握力增加≥8 kPa,需在4次注射后连续2次访视确认。
- B阶段主要终点为复发风险(首次aINCAT评分增加≥1分的时间)。
- A阶段主要终点在A阶段安全性人群中评估,B阶段主要终点在改良意向治疗人群中评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步研究以提供艾加莫德α长期疗效的数据及其与现有治疗方案的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives. Efgartigimod alfa, a human IgG1 antibody Fc fragment, has demonstrated efficacy and safety in patients with generalised myasthenia gravis. We evaluated the safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in adults with CIDP. METHODS: ADHERE, a multistage, double-blind, placebo-controlled trial, enrolled participants with CIDP from 146 clinical sites from Asia-Pacific, Europe, and North America. Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A). Those with confirmed evidence of clinical improvement (ECI; treatment responders) entered a randomised-withdrawal phase of 1000 mg subcutaneous efgartigimod PH20 weekly treatment versus placebo for a maximum of 48 weeks (stage B). Participants were randomised (1:1) through interactive response technology and stratified by their adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score change during stage A and their most recent CIDP medication within 6 months before screening. Investigators, the clinical research organisation, and participants were masked to the treatment. The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (≥1 points aINCAT decrease, ≥4 points [centile metric] Inflammatory Rasch-built Overall Disability Scale increase, or ≥8 kPa grip strength increase after four injections and two consecutive visits). The primary endpoint in stage B, evaluated in the modified intention-to-treat population, was the risk of relapse (time to first aINCAT increase of ≥1 points). ADHERE is registered with ClinicalTrials.gov (NCT04281472) and EudraCT (2019-003076-39) and is completed. FINDINGS: Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61·0-71·6) had confirmed ECI. In stage B, 221 participants were randomised (79 female, 142 male; 111 to subcutaneous efgartigimod PH20, 110 to placebo). Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0·39 [95% CI 0·25-0·61]; p<0·0001). 31 (27·9% [19·6-36·3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53·6% [44·3-63·0]) given placebo. In stage A, treatment-emergent adverse events (TEAEs) occurred in 204 (63%) participants and serious TEAEs in 21 (7%). In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo. Three deaths occurred: two in stage A (one non-related and one unlikely related to treatment) and one in stage B (placebo group). INTERPRETATION: ADHERE showed the efficacy of subcutaneous efgartigimod PH20 in reducing the risk of relapse versus placebo in people with CIDP who responded to treatment. Further studies are needed to provide data on the longer-term effects of efgartigimod alfa and how it compares with currently available treatment options. FUNDING: argenx.
引用
- Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024. PMID: 39304241. doi:10.1016/S1474-4422(24)00309-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。